EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?

Sejal Saglani, Laura Yates, Clare M Lloyd

European Journal of Immunology · 2023-08 · 53 (8)

DOI: 10.1002/eji.202249919 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Immunology, online erschienen am 03.04.2023. Verfasst von Sejal Saglani und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Interleukin-13, Asthma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is classically considered to be a disease of type 2 immune dysfunction, since many patients exhibit the consequences of excess secretion of cytokines such as IL‐4, IL‐5, and IL‐13 concomitant with inflammation typified by eosinophils. Mouse and human disease models have determined that many of the canonical pathophysiologic features of asthma may be caused by these disordered type 2 immune pathways. As such considerable efforts have been made to develop specific drugs targeting key cytokines. There are currently available multiple biologic agents that successfully reduce the functions of IL‐4, IL‐5, and IL‐13 in patients, and many improve the course of severe asthma. However, none are curative and do not always minimize the key features of disease, such as airway hyperresponsiveness. Here, we review the current therapeutic landscape targeting type 2 immune cytokines and discuss evidence of efficacy and limitations of their use in adults and children with asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-13AsthmaAdultChildHumansAnimalsMiceInterleukin-5Interleukin-4EosinophilsCytokines

Stichwörter der Autor:innen

AsthmaAsthma biologicsImmunoregulationtype 2

Substanzen

Interleukin-13Interleukin-5Interleukin-4Cytokines

Autor:innen und Institutionen

  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Zitieren

APA

Saglani, S., Yates, L., & Lloyd, C. M. (2023). Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?. European Journal of Immunology, 53(8). https://doi.org/10.1002/eji.202249919

Vancouver

Saglani S, Yates L, Lloyd CM. Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?. European Journal of Immunology. 2023;53(8). doi:10.1002/eji.202249919

BibTeX
@article{Saglani2023,
  author = {Saglani, Sejal and Yates, Laura and Lloyd, Clare M},
  title = {Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?},
  journal = {European Journal of Immunology},
  year = {2023},
  volume = {53},
  number = {8},
  doi = {10.1002/eji.202249919}
}
Kostenlos starten →